EP1232188B1 - Cyclodextrines substituees par des groupements fluoroalkyles, leur preparation et leur utilisation - Google Patents
Cyclodextrines substituees par des groupements fluoroalkyles, leur preparation et leur utilisation Download PDFInfo
- Publication number
- EP1232188B1 EP1232188B1 EP00956571A EP00956571A EP1232188B1 EP 1232188 B1 EP1232188 B1 EP 1232188B1 EP 00956571 A EP00956571 A EP 00956571A EP 00956571 A EP00956571 A EP 00956571A EP 1232188 B1 EP1232188 B1 EP 1232188B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cyclodextrin
- solvent
- group
- phase
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC(C(*)*1)C(*)OC1OC Chemical compound CC(C(*)*1)C(*)OC1OC 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0004—Preparation of sols
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Definitions
- Cyclodexrins are cyclic oligomers constructed from alpha-D-glucopyranosyl units in conformation chair connected by links 1-4, below also designated by cyclodextrinyl residue (s).
- Cyclodextrins can be represented by the following general formula I:
- Cyclodextrins have a form space in truncated cone. Primary alcohol functions are on the small base and alcohol functions secondary on the large base, which locates the hydrophilic character outside the cyclodextrins.
- the internal cavity is lined with hydrogen bonds linked to carbons 3 and 5 and to oxygen atoms glycosidics, which gives a relatively hydrophobic to the cyclodextrin cavity.
- Cyclodextrins alpha, beta, gamma, and many derivatives of these have been described since long as molecules capable of trapping certain small hydrophobic molecules or hydrophilic.
- the use of cyclodextrins to capture and protect lipophilic vitamins, aromas and some very fragile active ingredients made the subject of numerous patents and publications. So the Japanese patent JP 52/130904 reports the stabilization of vitamin D3 by inclusion in beta-cyclodextrin, the patent JP 56/139409 describes the inclusion of vitamin E in cyclodextrins, Belgian patent BE 888736 concerns stabilization of a drug, indomethacin in a methylated derivative of ⁇ -cyclodextrin.
- US-A-5,739,121 describes fluorinated cyclodextrin derivatives and their inclusion complexes with drug substances.
- Document JP-A-9 241 303 discloses fluorinated derivatives of cylodextrin having a perfluorooxyalkyl chain used as surface modifiers in the field of magnetic tapes the link arm X can be chosen from -O-CO- or -NH-CO- and the RF substituent being a perfluorooxyalkyl chain or perfluoroalkyl.
- cyclodextrin derivatives according to the invention are monosubstituted to persubstituted cyclodextrins on the hydroxyl groups in position 2 and / or 3 (secondary sites) by one or more identical or different fluoroalkyl groups.
- cyclodextrin derivatives according to the invention consist of 6 to 8 identical or different cyclodextrinyl residues of the following formula IV: where at least one of the groups Y of at least one of the 6 to 8 cyclodextrinyl residues represents a group of formula - (X) -RF, and Y when it is not a group of formula - (X) -RF is a group -OH, where RF and X are as defined in formula II above.
- alpha cyclodextrin derivatives include from 1 to 12 RF radicals
- derivatives of beta cyclodextrins comprise from 1 to 14 RF radicals
- the gamma cyclodextrin derivatives include from 1 to 16 RF radicals.
- cyclodextrin derivatives belonging to this class very particularly preferred are those in which X is -CO-O or -O-CO-, and RF is from C 3 F 7 to C 14 F 29 .
- Cyclodextrin derivatives according to the invention can be prepared as follows: we proceed to a step of protection of primary OH with chlorosilane then performs a secondary OH perfluorination, and deprotects primary OH.
- Cyclodextrin derivatives according to the invention are remarkable in that they have enabled the Inventors to develop a new transportation system for very diverse active substances. Indeed, the perfluorinated cyclodextrins according to the invention have many advantages compared to derivatives in particular acrylics used for particle preparation submicrones containing an active molecule. Their main advantage is that unlike other acrylic derivatives including polymerization requires an energy intake likely to harm the stability of the active ingredient incorporated, the cyclodextrins perfluorinated do not polymerize to form systems carriers.
- the cyclodextrin derivatives according to the invention allow a rate of incorporation of a very high active substance. This is due to the possibility of triple charge, first, a charge in the network, second in the cyclodextrin cavity provided that the encapsulated molecule has a conformation suitable in relation to the cavity, and thirdly a charge adsorbed on the surface of the particle formed by the cyclodextrin derivative of the invention.
- the perfluorinated cyclodextrins according to the invention have the advantage of dissolving the gases.
- the cyclodextrin derivatives according to the invention make it possible to prepare particles capable transport or vectorize very various, such as oxygen or other gases, due to the high capacity of fluorides to dissolve gases, and as a result present many applications like for example temporary or other blood substitutes, preoperative hemodilution, treatment of ischemia myocarditis and cerebral, cardioplegia, perfusion, potentiation of radio and chemotherapy cancer, organ preservation and diagnosis.
- the derivatives of cyclodextrin of the invention make it possible to prepare colloidal dispersions useful for making shapes injectable with insoluble drugs, or stabilize a drug active ingredient.
- the particles of the invention also find applications in fields other than those of medicine, such as in phytopharmacy, where they used to carry insecticides or pesticides. Due to their size, the particles of the invention easily penetrate through the cuticle. The weak viscosity of the dispersion allows a very precise spraying easy as very small droplets more effective because more covering.
- the particles of the invention can transport anti-radical substances or oxygen in the dermis.
- the particles of the invention also find applications in the field of aerobic cultures, fermentation and organ conservation, due to the transport properties in inert liquid matrix of reactive gases (O 2 , hydrogen, carbon monoxide or dioxide) or not (nitrogen or rare gases).
- the particles of the invention allow have dispersions useful for conveying pigments, reagents, strippers in dispersion form aqueous of very low viscosity, easy to spray or apply, and which can, if necessary, be made viscous, even adhesive (resuspension of particles in a suitable vehicle).
- the reduced size particles leads to a very fine deposit and to a very great homogeneity, for example of pigmentation allowing their use in printing, reprography, surface treatment of textiles and fibers, in photography, lubrication, agriculture.
- the invention therefore also relates to nanoparticles smaller than about 1000 nm consisting of cyclodextrin derivatives described previously and possibly one or more active substances.
- the cyclodextrin derivatives used for the manufacture of nanoparticles of size less than 1000 nm which encapsulate one or more active substance (s) according to the invention consist of 6 to 8 identical or different cyclodextrinyl residues of the following formula II: where at least one of the groups Y of at least one of the 6 to 8 cyclodextrinyl residues represents a group of formula - (X) -RF, and Y when it is not a group of formula - (X) -RF is a group -OH, where RF is a fluroalkyl radical of 1 to 20 carbons or more, the carbon chain of which is optionally interrupted by one or more heteroatoms such as oxygen or sulfur, linear or branched by an alkyl or fluroalkyl group saturated or not saturated with 1 to 20 carbons or more, neutral, zwitterionic, charged functionalized for example by one or more groups - COOH, -OH, CF3, and X represents a link arm
- a fluroalkyl RF radical containing more than 20 carbon atoms also falls within the scope of the present invention.
- the fluroalkyl RF radical can be linear or branched by an alkyl or fluroalkyl chain, saturated or unsaturated, comprising from 1 to 20 carbons or more, neutral, zwitterionic, charged functionalized or within the chain or at least one of its ends.
- a fluoroalkyl chain according to the invention, the following group may be mentioned: -CF 2 -CF 2 -O-CF 2 -CF 2 -O-CF 3 .
- the linking arm X can be a covalent bond or an atom or a group linking the carbon atom of the cyclodextrinyl residue and the fluroalkyl RF radical, such as: -NH-, -CO-O-, -O-CO- , -CO-NH-, -NH-CO-, -O-, -O- (CH 2 ) n -, - (CH 2 ) n -CO-O-, -O-CO-NH-, PO 4 - or S.
- the nanoparticles of the invention are spherical in type vesicular. These nanoparticles made it possible to prepare a new dispersible nanovesicular colloid system.
- nanocapsules of the type gallbladder whose diameter varies from a few tens to several hundred nanometers.
- the preparation of nanocapsules has the advantage of being reversible. He is possible to dissolve and prepare nanocapsules from this solution according to the procedure.
- the modified cyclodextrin is in particular a natural or modified cyclodextrin, modified by route chemical, biochemical, enzymatic or other, by addition aliphatic chain which may contain one or more functional groups, at the carbon site level primary or secondary, such as beta-cyclodextrin with 3 carbons, 12 carbons, 14 carbons or more or less.
- the active molecule can be a medicinal principle or a drug precursor, a biological reagent or a cosmetic principle. The invention makes it possible to obtain modified cyclodextrin nanocapsules alone (usable as is) or with the active molecule.
- the solvent in phase (i) which is acetone or a mixture of solvents is found in particular at a temperature ranging from 0 ° to 50 ° C for example approximately at the ambient temperature.
- the oil can be a vegetable oil or mineral, or any oily substance, for example oil olive, benzyl benzoate, isopropyl myristate, fatty acid glycerides (eg a Miglyol®), or the like.
- the non-solvent in phase (ii), which is water or an aqueous mixture, is in particular at a temperature from 0 ° to 100 ° C or more (under pressure atmospheric), for example around temperature boiling.
- the concentration of cyclodextrin changed in phase (i) may vary.
- the volume ratio phase (i) / phase (ii) can vary from 0.1 to 1, preferably from 0.2 to 0.6.
- colloidal suspension of nanocapsules can be concentrated, sterilized at will, buffered (for example at physiological pH), lyophilized.
- the invention makes it possible to obtain nanocapsules perfluorinated cyclodextrins, in particular from 150 to 300 nm.
- nanoparticles are likely to contain one or more active ingredients.
- active ingredient more particularly agents pharmaceutical, cosmetic, dermatological or even food, but it can also be substances various assets useful for multiple applications previously given.
- the encapsulation rate is still very high in the case of lipophilic products; 200 mg cyclodextrin modified for example to encapsulate 3 ml of benzyl benzoate or 230 mg of progesterone and 0.6 ml of oil used as support.
- Active substances insoluble in organic and water-soluble solvents can also be encapsulated. It is enough that they present a certain affinity for the lipophilic phase; the process nanocapsule preparation is analogous. Simply solubilize the active substance in the aqueous phase containing cyclodextrin derivatives. The rate encapsulation depends on the partition coefficient of the active substance and its lipophilicity.
- the nanocapsules of the invention are autoclavable for more than 15 min at 120 ° C under a pressure of 1 bar.
- the nanocapsules of the invention are stable at ultracentrifugation. After ultracentrifugation at 220,000 g for 2 h 30 min, most of the nanocapsules can be easily redispersed in water.
- the active substance, contained in nanocapsules of the invention, is more particularly a drug molecule for human or veterinary use or a product for diagnosis.
- a drug molecule more particularly, chemicals endowed with pharmacological properties and for example, antimitotic or antineoplastic substances such as methotrexate, actinomycin D, adriamycin, daunorubicin, bleomycin, and vincristine or antibiotic substances such as penicillins, cephalosporins and nalidixic acid, antibiotics aminoglycoside type and those of the virginiamycin and hormonal substances, especially steroid hormones.
- antibiotic substances such as penicillins, cephalosporins and nalidixic acid, antibiotics aminoglycoside type and those of the virginiamycin and hormonal substances, especially steroid hormones.
- These drug molecules can in particular be high-weight chemical compounds molecular like insulin and heparin.
- the nanoparticles according to the invention can also contain organic products such as antigens, enzymes, proteins, viruses or constituents of viruses, bacteria or cells.
- the nanoparticles according to the invention can also contain a diagnostic product such as fluorescein and radioactive human serum albumin.
- the nanoparticles according to the invention can also contain a diagnostic product, including lipophilic radiopaque products such as oils iodine.
- nanoparticles of the invention can be administered with or without a suitable oral excipient, under cutaneous, intradermal, intramuscular or intravenous and their diffusion in the tissues makes them particularly interesting for general treatments.
- the nanoparticles of the invention are spherical in type matrix. These nanoparticles, like the previous ones, have a size less than 1000 nm and will therefore also be designated nanospheres. They may or may not contain one or more several active substances.
- the solvent in the phase of step (a) which is acetone or a mixture of solvents is found advantageously at a temperature ranging from 0 ° to 50 ° C by example approximately at room temperature.
- the non-solvent in the phase of step (b) which is water or an aqueous mixture, is found advantageously at a temperature ranging from 0 ° to 100 ° C or plus (at atmospheric pressure), for example around the boiling point.
- the concentration of cyclodextrin derivatives in the phase of step (a) may vary.
- the volume report for stage (a) / the phase of step (b) can vary from 0.1 to 1, preferably from 0.2 to 0.6.
- the invention therefore also relates to a suspension colloidal spherical nanoparticles of the matrix type.
- This constitutes a system for transporting derivatives of perfluorinated cyclodextrin alone or in combination with one or more active agent.
- This colloidal suspension can be concentrated, sterilized, buffered will (e.g. physiological pH), lyophilized.
- the nanoparticles of the invention in this colloidal suspension have a size on the order of 150 to 300 nm.
- nanoparticles matrix type sphericals of the invention contain at least within their network an active molecule for example a drug molecule for human or veterinary use or a product for diagnosis.
- drugs endowed with pharmacological properties and for example, antimitotic or antineoplastic substances such as methotrexate, actinomycin D, adriamycin, daunorubicin, bleomycin, and vincristine or antibiotic substances such as penicillins, cephalosporins and nalidixic acid, antibiotics aminoglycoside type and those of the virginiamycin and hormonal substances, especially steroid hormones.
- antibiotic substances such as penicillins, cephalosporins and nalidixic acid, antibiotics aminoglycoside type and those of the virginiamycin and hormonal substances, especially steroid hormones.
- drug molecules can in particular be high-weight chemical compounds molecular like insulin and heparin and expression
- drug molecule also includes products biologicals like antigens, enzymes, proteins, viruses or constituents of viruses, bacteria or cells.
- Conveyor systems according to the invention may also contain a product for diagnosis such as fluorescein and radioactive human serum albumin.
- Example 1 Synthesis of a ⁇ -cylodextrin per 2,3 di-O-pentadecafluoro-octanoyl, per 6-O-terbutyldimethylsilyl .
- Chlorosilane in solution in 45ml of pyridine is then added dropwise at temperature ambient under nitrogen and agitation is maintained for 4 hours./
- reaction medium is then thrown into 400ml of ice water then filtered and washed with the minimum of water (50ml).
- the solid thus isolated is taken up in 100ml of CHCl 3 and washed with 50ml of 3% HCl, 50ml of saturated NaHCO 3 and 50ml of water.
- the white, powdery solid thus obtained is formed with an average yield of 85-90%.
- the degreased sodium hydride is placed in suspension in 25ml of dichloromethane and the ⁇ CD PTBDMS in solution in 25ml of dichloromethane is then added drip.
- reaction medium is then brought to solvent reflux for 30 minutes and the fluorinated derivative, in solution in dichloromethane (25 ml) is then added (greenish color of the mixture).
- Control of the operations is carried out using analyzes of the reaction medium (thin layer chromatography and HPLC).
- the purification is carried out on silica gel with a mobile phase and a gradient of solvent CH 2 Cl 2 / MeOH / AcOEt.
- the purity of the final product is controlled by HPLC (C18 grafted silicas, methanol-water reverse phase) and its structural characteristics are established using mass spectrometry (determination of molecular mass and fractionation, MALDI TOF and FAB), IRFT (presence of the carbonyl motif of the ester and essentially perfluorinated chains) and NMR 300 or 500 MHz (integration ratio of the anomers and of the signals of the groups carried by the silicon bonded to oxygen in position 6, characteristic values of carbonyls in positions 2 and 3 in 13 C spectra, measurement of couplings between nuclei, fluorine spectra).
- HPLC C18 grafted silicas, methanol-water reverse phase
- Example II Preparation of a system colloidal nanovesicular dispersible based on perfluorinated cyclodextrins and its use for vectorize active ingredients.
- Cyclodextrin derivatives according to the invention allow to prepare spherical particles of the type vesicular, less than 1000 nm in size (nanocapsules) and containing or not an active molecule.
- Phase 1 is added with stirring magnetic in phase 2.
- the medium immediately becomes opalescent by formation of cyclodextrin nanocapsules changed.
- the average size of the nanocapsules measured by a laser beam diffractometer
- the suspension can be concentrated under reduced pressure at desired volume, for example 5 ml or more or less.
- the nanocapsules obtained have a size of 300 nm with an average dispersion index of 0.5.
- the nanocapsules have an average size of 500 nm with a average dispersion index of 0.6.
- nanocapsules have an average size of 320 nm with an average dispersion index of 1.
- the suspension remains stable over time and exhibits, after 5 months of storage, no sedimentation irreversible, nor variation in the size of the nanocapsules.
- the suspension remains stable over time and exhibits, after 5 months of storage, no sedimentation irreversible, nor variation in the size of the nanocapsules.
- the nanocapsules obtained have an average size of 320 nm with a dispersion index of 0.5. After ultracentrifugation and determination of indomethacin in the dispersing phase, the amount of active ingredient incorporated in the nanocapsules represents 90% of the initial quantity.
- Nanocapsules obtained have an average size of 120 nm and an index of 0.2 dispersion. After ultracentrifugation and dosing of progesterone in the dispersing phase, the amount of active ingredient incorporated in nanocapsules represents 90% of the initial quantity.
- the nanocapsules obtained have an average size of 130 nm and a dispersion index of 0.2.
- Example III Preparation of a colloidal suspension based on perfluorinated cyclodextrins and its use for transporting active ingredients .
- Phase 1 is added with stirring magnetic in phase 2.
- the medium immediately becomes opalescent by formation of nanoparticles based on modified cyclodextrin.
- the average size of the systems transporters measured by a laser beam diffractometer is 180 nm with a average dispersion index of 0.08.
- the suspension can be concentrated under pressure reduced to desired volume, for example 5 ml or more or less.
- the nanoparticles obtained have a size of 200 nm with an average dispersion index of 0.5.
- the nanoparticles have an average size of 200 nm with a average dispersion index of 0.6.
- the aqueous phase is supplemented with 90 mg of chloride sodium.
- concentration of the suspension of nanospheres up to a volume of 10 ml, corresponding taking sodium chloride into isotonia with the blood, the nanospheres have an average size of 200 nm with an average dispersion index of 1.
- the suspension remains stable over time and exhibits, after 5 months of storage, no sedimentation irreversible, nor variation in the size of the nanospheres.
- the suspension remains stable over time and exhibits, after 5 months of storage, no sedimentation irreversible, nor variation in the size of the nanospheres.
- the average size of the nanospheres is 175 nm with an average dispersion index of 0.08.
- the rate of ATP encapsulation, measured after ultracentrifugation is close to 100% of the quantity used.
- the nanospheres obtained have an average size 200 nm with a dispersion index of 0.5. After ultracentrifugation and determination of indomethacin in the dispersing phase, the amount of active ingredient incorporated in the nanospheres represents 70% of the quantity initial.
- the nanospheres obtained have an average size of 200 nm and an average dispersion index of 1. After ultracentrifugation and dosing of doxorubicin in the dispersing phase, the amount of active ingredient incorporated in the nanospheres represents 60% of the quantity initial.
- the nanospheres obtained have an average size of 120 nm and a dispersion index of 0.2. After ultracentrifugation and assay of progesterone in the dispersing phase, the amount of active ingredient incorporated in the nanospheres represents 90% of the initial quantity.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
Description
- les cyclodextrines alpha comprennent 6 groupes hydroxyles primaires en position 1, et 12 groupes hydroxyles secondaires en position 2 et 3;
- les cyclodextrines bêta comprennent 7 groupes hydroxyles primaires en position 1, et 14 groupes hydroxyles secondaires en position 2 et 3;
- les cyclodextrines gamma comprennent 8 groupes hydroxyles primaires en position 1, et 24 groupes hydroxyles secondaires en position 2 et 3;
- d'atteindre de nouveaux sites d'action, en particulier intracellulaires, voire intralysomiaux,
- de mettre en oeuvre de nouvelles voies d'administration en augmentant la stabilité et/ou l'absorption des principes actifs, ou en permettant la réalisation de formes injectables par voie intravasculaire, de principes actifs insolubles
- de modifier la distribution tissulaire des principes actifs, par un meilleur ciblage vers des sites d'actions favorables et/ou un détournement des sites d'effets indésirables voire toxiques (amélioration de l'index thérapeutique).
- RF représente de CF3 à C14F29,
- X représente -CO-O-, -CO-, amine et amide.
- La pyridine est distillée sur CaH2
- La β-CD est séchée par entraínement azéotropique à la pyridine ou par chauffage prolongé en étuve à vide.
- .Le chlorosilane et l'imidazole sont les produits commerciaux purs (Acros Organics France ou Sigma-Aldrich).
- Le THF est distillé sur CaH2 et la verrerie séchée à l'étuve
- L'acide perfluoré et le carbonyle-diimidazole sont les réactifs commerciaux purs (Fluka).
le milieu devient homogène et jaunit.
soit un léger excès des réactifs (16 équivalents) pour l'introduction de deux motifs perfluorés par unité de sucre dans la cyclodextrine.
- NaH est dégraissé plusieurs fois avec de l'hexane et CH2Cl2 est distillé sur CaH2.
- ballon tricol de 250ml avec réfrigérant, garde desséchante et ampoule de coulée. Agitation magnétique avec barreau aimanté, bain marie.
- béta cyclodextrine perfluorées à 8 carbones : 50 mg
- acétone : 50 ml
- benzoate de benzyle : 2 ml
- Pluronic® F68 : 62,5 mg
- eau déminéralisée ou distillée : 25 ml
- bêta cyclodextrine perfluorées à 8 carbones : 50 mg
- acétone : 50 ml
- Pluronic® F68 : 62,5 mg
- eau déminéralisée ou distillée : 25 ml
Claims (14)
- Dérivé de cyclodextrine caractérisé en ce qu'il est constitué de 6 à 8 résidus cyclodextrinyles identiques ou différents de formule IV suivante : où l'un au moins des groupes Y de l'un au moins des 6 à 8 résidus cyclodextrinyles représente un groupement de formule -(X)-RF, et Y lorsqu'il n'est pas un groupement de formule -(X)-RF est un groupe -OH, où RF est un radical fluoroalkyle de 1 à 20 carbones ou plus dont la chaíne carbonée est éventuellement interrompue par un ou plusieurs hétéroatomes comme l'oxygène ou le soufre, linéaire ou ramifié par un groupe alkyle ou fluoroalkyle, saturée ou non de 1 à 20 carbones ou plus, neutre, zwitterionique, chargée, fonctionnalisée par exemple par un ou plusieurs groupes -COOH, -OH, -CF3, et X représente un bras de liaison entre un atome de carbone et le groupement de formule RF
- Dérivé de cyclodextrine selon la revendication 1, caractérisé en ce que RF représente de C3F7 à C14F29.
- Dérivé de cyclodextrine selon l'une des revendications 1 ou 2, caractérisé en ce que le bras de liaison X est choisi parmi une liaison covalente ou un atome ou un groupe liant l'atome de carbone du résidu cyclodextrinyle et le radical fluoroalkyl RF.
- Dérivé de cyclodextrine selon l'une des revendications 1 à 3, caractérisé en ce que le bras de liaison X est choisi parmi : -NH-, -CO-O-, -O-CO-, -CO-NH-, -NH-CO-, -O-, -O-(CH2)n-, -(CH2)n-CO-O-, -O-CO-NH-, -PO4 -, -S-.
- Nanoparticule de taille inférieure à 1000 nm, caractérisée en ce qu'elle est constituée :d'un ou plusieurs dérivés de cyclodextrine de formule II suivante : où l'un au moins des groupes Y de l'un au moins des 6 à 8 résidus cyclodextrinyles représente un groupement de formule -(x)-RF, et Y lorsqu'il n'est pas un groupement de formule -(X)-RF est un groupe -OH, où RF et X sont comme définis dans la formule IV ci-dessus,et d'une (ou plusieurs) substance(s) active(s),
- Nanoparticule selon la revendication 5, caractérisée en ce que la substance active est un principe actif utile en médecine humaine ou animal, un produit de diagnostic.
- Nanoparticule selon la revendication 5, caractérisée en ce que la substance active est un gaz.
- Nanoparticule selon la revendication 7, caractérisée en ce que ledit gaz est l'oxygène.
- Nanoparticule selon l'une des revendications 5 à 8, caractérisée en ce qu'elle est sphérique de type vésiculaire.
- Un système colloïdal nanovésiculaire dispersible constitué de nanoparticules selon la revendication 9.
- Nanoparticule selon l'une des revendications 5 à 8, caractérisée en ce qu'elle est sphérique de type matriciel.
- Une suspension colloïdale constituée de nanoparticules selon la revendication 11.
- Procédé de préparation d'une suspension colloïdale selon la revendication 12, caractérisé en ce qu'il comprend les étapes suivants :a) on prépare une phase liquide constituée essentiellement par une solution de dérivés de cyclodextrine selon l'invention dans un solvant ou mélange de solvants contenant ou non un surfactif et pouvant être additionnée d'une molécule active,b) on prépare une seconde phase liquide constituée essentiellement par de l'eau ou d'un mélange aqueux, contenant ou non un surfactif et pouvant être additionnée d'une molécule active,c) on ajoute sous agitation modérée, l'une des phases liquides préparés aux étapes précédentes à l'autre, de manière à obtenir pratiquement instantanément une suspension colloïdale,d) éventuellement, on élimine tout ou une partie du solvant ou du mélange de solvants et du non-solvant ou du mélange de non-solvants, de manière à obtenir une suspension colloïdale de concentration voulue ou une poudre.
- Procédé de préparation d'un système colloïdal nanovésiculaire dispersible selon la revendication 10, caractérisé en ce qu'il comprend les étapes suivants :a) on prépare une phase liquide constituée essentiellement par une solution de dérivés de cyclodextrine selon l'une des revendications 1-4 dans un solvant ou mélange de solvants contenant obligatoirement de l'huile, contenant ou non un surfactif et pouvant être additionnée d'une molécule active,b) on prépare une seconde phase liquide constituée essentiellement par de l'eau ou d'un mélange aqueux, contenant ou non un surfactif et pouvant être additionnée d'une molécule active,c) on ajoute sous agitation modérée, l'une des phases liquides préparés aux étapes précédentes à l'autre, de manière à obtenir pratiquement instantanément un système colloïdal nanovésiculaire dispersible,d) éventuellement, on élimine tout ou une partie du solvant ou du mélange de solvants et du non-solvant ou du mélange de non-solvants, de manière à obtenir un système colloïdal nanovésiculaire dispersible de concentration voulue ou une poudre.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK00956571T DK1232188T3 (da) | 2000-07-28 | 2000-07-28 | Cyclodextriner substitueret med fluoralkylgrupper, deres fremstilling og deres anvendelse |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9909863A FR2796955B1 (fr) | 1999-07-29 | 1999-07-29 | Cyclodextrines monosubstitues a persubstitues par des groupements fluoroalkyles, leur preparation et leur utilisation |
FR9909863 | 1999-07-29 | ||
PCT/FR2000/002192 WO2001009195A1 (fr) | 1999-07-29 | 2000-07-28 | Cyclodextrines monosubstitues a persubstitues par des groupements fluoroalkyles, leur preparation et leur utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1232188A1 EP1232188A1 (fr) | 2002-08-21 |
EP1232188B1 true EP1232188B1 (fr) | 2004-10-27 |
Family
ID=9548671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00956571A Expired - Lifetime EP1232188B1 (fr) | 1999-07-29 | 2000-07-28 | Cyclodextrines substituees par des groupements fluoroalkyles, leur preparation et leur utilisation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1232188B1 (fr) |
AT (1) | ATE280784T1 (fr) |
DE (1) | DE60015380T2 (fr) |
ES (1) | ES2231241T3 (fr) |
FR (1) | FR2796955B1 (fr) |
PT (1) | PT1232188E (fr) |
WO (1) | WO2001009195A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764638A (zh) * | 2012-07-23 | 2012-11-07 | 中国农业大学 | 2,3,6-三-O-辛酰基-β-环糊精在制备气相色谱手性固定相中的应用 |
CH710884A1 (de) * | 2015-03-17 | 2016-09-30 | Zhaw Zurich Univ For Applied Sciences Icbc Inst For Chemistry & Biological Chemistry | Verfahren zur gaschromatographischen Trennung eines Enantiomerengemisches. |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100366816C (zh) * | 2005-01-19 | 2008-02-06 | 财团法人工业技术研究院 | 缓释型防虫与防微生物织物表面改质方法 |
DE102009043717A1 (de) * | 2009-10-01 | 2011-04-07 | Westfälische-Wilhelms Universität Münster | Fluorcyclodextrine |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9325330D0 (en) * | 1993-12-10 | 1994-02-16 | Univ Toronto | Fluorocyclodextrin drug delivery system |
JPH09241303A (ja) * | 1996-03-12 | 1997-09-16 | Hitachi Ltd | 含フッ素化合物および表面改質剤、これを用いた磁気記録媒体 |
-
1999
- 1999-07-29 FR FR9909863A patent/FR2796955B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-28 DE DE60015380T patent/DE60015380T2/de not_active Expired - Fee Related
- 2000-07-28 PT PT00956571T patent/PT1232188E/pt unknown
- 2000-07-28 AT AT00956571T patent/ATE280784T1/de not_active IP Right Cessation
- 2000-07-28 EP EP00956571A patent/EP1232188B1/fr not_active Expired - Lifetime
- 2000-07-28 ES ES00956571T patent/ES2231241T3/es not_active Expired - Lifetime
- 2000-07-28 WO PCT/FR2000/002192 patent/WO2001009195A1/fr active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764638A (zh) * | 2012-07-23 | 2012-11-07 | 中国农业大学 | 2,3,6-三-O-辛酰基-β-环糊精在制备气相色谱手性固定相中的应用 |
CH710884A1 (de) * | 2015-03-17 | 2016-09-30 | Zhaw Zurich Univ For Applied Sciences Icbc Inst For Chemistry & Biological Chemistry | Verfahren zur gaschromatographischen Trennung eines Enantiomerengemisches. |
Also Published As
Publication number | Publication date |
---|---|
PT1232188E (pt) | 2005-03-31 |
DE60015380D1 (de) | 2004-12-02 |
FR2796955A1 (fr) | 2001-02-02 |
EP1232188A1 (fr) | 2002-08-21 |
FR2796955B1 (fr) | 2006-02-10 |
ES2231241T3 (es) | 2005-05-16 |
ATE280784T1 (de) | 2004-11-15 |
WO2001009195A1 (fr) | 2001-02-08 |
DE60015380T2 (de) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0646003B1 (fr) | Preparation et utilisation de nouveaux systemes colloidaux dispersibles a base de cyclodextrine, sous forme de nanospheres | |
CN102114246B (zh) | 生物体病灶部位特异性释药的两亲性多糖衍生物载体及其药学组合物的制备和应用 | |
WO2008102065A1 (fr) | Emulsions fluorescentes pour l'imagerie optique | |
WO1995035101A1 (fr) | Nanoparticules stabilisees et filtrables dans des conditions steriles | |
US7682635B2 (en) | Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds | |
EP2350168A1 (fr) | Copolymères à blocs à base de polysaccharide et de polypeptide, les vésicules constituées de ces copolymères et leur utilisation | |
JPH08510232A (ja) | タキソールまたはタキソテレまたはイチイ抽出物と、シクロデキストリンとから成る封入複合体、該複合体の製造及び使用 | |
EP1177217B1 (fr) | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes | |
CN113264906A (zh) | 多西他赛二聚体小分子前药及其自组装纳米粒的构建 | |
KR101542138B1 (ko) | 폴리도파민계 나노입자, 불수용성 약물이 표면에 코팅된 폴리도파민계 나노입자 및 이들의 제조방법 | |
EP1232188B1 (fr) | Cyclodextrines substituees par des groupements fluoroalkyles, leur preparation et leur utilisation | |
EP0646002B1 (fr) | Preparation et application de nouveaux systemes colloidaux nanovesiculaires dispersibles a base de cyclodextrine, sous forme de nanocapsules | |
EP1293248B1 (fr) | Nouveau système dispersable colloidale basé sur calixarene, sous forme de nanoparticules | |
CN113278092B (zh) | 一种聚合物载体材料及其制剂和应用 | |
T Perchyonok et al. | Cyclodextrins as oral drug carrier molecular devices: Origins, reasons and in-vitro model applications | |
Farsana et al. | Hydrogel based nanosponges drug delivery for topical applications-A updated review | |
WO2014191645A1 (fr) | Microparticules et nanoparticules auto-associatives composées de protéines | |
CN115282126B (zh) | 一种甘露糖修饰的白花丹醌纳米结构脂质载体及其制备方法和用途 | |
FR2515960A1 (fr) | Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application | |
CN105616340B (zh) | 一种负载10-羟基喜树碱的超分子水凝胶体系及其制备方法 | |
Yang et al. | Advancements in the Preparation of Cyclodextrin-based Metal-Organic Frameworks for Drug Delivery | |
CN111494342A (zh) | 一种靶向叶酸受体的负载紫杉醇的纳米粒子的制备方法 | |
KR20220094959A (ko) | 솔잎 활성성분을 함유하는 화장료조성물 | |
KR20210070823A (ko) | 당근 지상부 활성성분을 함유하는 화장료조성물 | |
CN112999196A (zh) | 用于长效稳定释放的吗替麦考酚酯纳米制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: CYCLODEXTRINS SUBSTITUTED BY FLUOROALKYL GROUPS, PREPARATION AND USE THEREOF |
|
RTI1 | Title (correction) |
Free format text: CYCLODEXTRINS SUBSTITUTED BY FLUOROALKYL GROUPS, PREPARATION AND USE THEREOF |
|
RTI1 | Title (correction) |
Free format text: CYCLODEXTRINS SUBSTITUTED BY FLUOROALKYL GROUPS, PREPARATION AND USE THEREOF |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: FRENCH |
|
REF | Corresponds to: |
Ref document number: 60015380 Country of ref document: DE Date of ref document: 20041202 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ABREMA AGENCE BREVETS ET MARQUES GANGUILLET & HUMP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20050400309 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20050126 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20050321 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2231241 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20050728 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20080815 Year of fee payment: 9 Ref country code: DE Payment date: 20080807 Year of fee payment: 9 Ref country code: DK Payment date: 20080731 Year of fee payment: 9 Ref country code: ES Payment date: 20080822 Year of fee payment: 9 Ref country code: LU Payment date: 20080826 Year of fee payment: 9 Ref country code: PT Payment date: 20080703 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20080814 Year of fee payment: 9 Ref country code: FI Payment date: 20080731 Year of fee payment: 9 Ref country code: FR Payment date: 20080801 Year of fee payment: 9 Ref country code: IE Payment date: 20080730 Year of fee payment: 9 Ref country code: IT Payment date: 20080731 Year of fee payment: 9 Ref country code: MC Payment date: 20080819 Year of fee payment: 9 Ref country code: NL Payment date: 20080731 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20080619 Year of fee payment: 9 Ref country code: GB Payment date: 20080806 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20080916 Year of fee payment: 9 Ref country code: SE Payment date: 20080731 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20080619 Year of fee payment: 9 |
|
BERE | Be: lapsed |
Owner name: *UNIVERSITE DE ROUEN Effective date: 20090731 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20100128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
EUG | Se: european patent has lapsed | ||
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090728 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20100201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20100331 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100128 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100202 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090731 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20090729 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090729 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100204 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090728 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090729 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100201 |